Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Probi AB (publ)    PROB   SE0001280355

PROBI AB (PUBL)

(PROB)
  Report
Delayed Quote. Delayed NASDAQ OMX STOCKHOLM - 05/29 11:29:48 am
260.5 SEK   +2.96%
05/14PROBI PUBL : A true pioneer in probiotic research is elected NutraChampion 2020
AQ
05/14PROBI AB (PUBL) : Ex-dividend day for final dividend
FA
05/13PROBI PUBL : ´s Annual General Meeting 2020
PU
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Probi publ : and Viva5 announce strategic joint venture to address growing market segments

share with twitter share with LinkedIn share with facebook
share via e-mail
03/24/2020 | 08:01am EDT

Swedish based probiotic specialist Probi enters a strategic joint venture with the US based health and wellness company Viva5 Group.

The joint venture VivaPro LLC will address the global market in probiotic related business areas. VivaPro will be governed as a standalone company operating out of US. Viva5 Group and Probi will own 51 and 49% share respectively and will have equal representation on the Board of Directors. Probi will have an option to acquire the share majority of the company at a later stage.

The joint venture will focus on exploring, researching and co-developing products in probiotic related market segments adjacent to existing core business areas of the two companies.

"With this strategic joint-venture we bring together the distinct capabilities of Probi and Viva5 in order to meet the increased consumer interest and demand for consumer friendly applications in areas such as functional food, beverages and pet health.", says Albert Dahbour, Executive Vice President, Viva5.

Probi manufactures and supplies the consumer healthcare and food industry with effective and well-documented probiotics with proven health benefits based on scientific research. Today, Probi is primarily present in the consumer healthcare market with dietary supplements and in selected food and beverage applications. The joint venture will address new and attractive market niches with the target to broaden the market reach for Viva5 and Probi.

Tom Rönnlund, CEO, Probi continues: "This joint venture is an important step in our commercial efforts to address new and attractive market niches. Even in these turbulent times we see great opportunities to jointly build a successful business, based on our longstanding relationship and confidence in our respective abilities to create scientific and commercial success."

 

FOR FURTHER INFORMATION, CONTACT:
Fabian Skärvad, Europe and Asia, Probi, tel +46 763350319, e-mail: Fabian@vivapro.com
Albert Dahbour, US, Viva5, tel +1 949 637 295, e-mail: Albert@vivapro.com

 

ABOUT PROBI
Probi is a world leader within probiotics. Our vision is to help people live healthier lives by delivering effective and well-documented probiotics, with proven health benefits based on scientific research. Probi offers dedicated probiotic expertise and partnership all the way from R&D to finished products for companies within the consumer healthcare and food industry. Our GMP certified manufacturing facilities produce probiotics in custom made formats with value-adding delivery technologies. Founded by scientists in Sweden 1991, Probi is a multinational company with 4 centers of excellence, active in more than 40 markets around the world and holding over 400 patents worldwide. Read more at www.probi.com.

 

ABOUT VIVA5
Viva 5 Corporation is a leading health and wellness company focused on innovation and operating in a variety of channels both in the USA and internationally. Viva 5 specializes in developing innovative, proprietary, and efficacious consumer products that create incremental revenue opportunities for its partners worldwide. For more information, please visit www.viva5corp.com

Probi is a world leader within probiotics. Our vision is to help people live healthier lives by delivering effective and well-documented probiotics, with proven health benefits based on scientific research. Probi offers dedicated probiotic expertise and partnership all the way from R&D to finished products for companies within the consumer healthcare and food industry. Our GMP certified manufacturing facilities produce probiotics in custom made formats with value-adding delivery technologies. Founded by scientists in Sweden 1991, Probi is a multinational company with 4 centers of excellence, active in more than 40 markets around the world and holding over 400 patents worldwide. Read more at www.probi.com.

https://news.cision.com/probi/r/probi-and-viva5-announce-strategic-joint-venture-to-address-growing-market-segments,c3067217

https://mb.cision.com/Main/1556/3067217/1216867.pdf

https://news.cision.com/probi/i/vivapro-logo,c2765226

(c) 2020 Cision. All rights reserved., source Press Releases - English

Stocks mentioned in the article
ChangeLast1st jan.
PROBI AB (PUBL) 2.96% 260.5 Delayed Quote.17.34%
SYMRISE AG 0.57% 98.4 Delayed Quote.4.90%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on PROBI AB (PUBL)
05/14PROBI PUBL : A true pioneer in probiotic research is elected NutraChampion 2020
AQ
05/14PROBI AB (PUBL) : Ex-dividend day for final dividend
FA
05/13PROBI PUBL : ´s Annual General Meeting 2020
PU
05/13PROBI PUBL : Annual General Meeting 2020
AQ
04/24Q1 2020 : A solid start to the year
AQ
04/21PROBI PUBL : Presentation of Probi's Q1 report 2020
PU
04/21PROBI PUBL : Presentation of Probi's Q1 report 2020
AQ
04/08PROBI PUBL : publishes Annual and Sustainability Report for 2019
AQ
04/07PROBI PUBL : Notice to Annual General Meeting in Probi AB (publ)
AQ
03/24PROBI PUBL : and Viva5 announce strategic joint venture to address growing marke..
AQ
More news
Financials
Sales 2020 665 M 70,6 M 70,6 M
Net income 2020 71,0 M 7,54 M 7,54 M
Net cash 2020 222 M 23,6 M 23,6 M
P/E ratio 2020 41,6x
Yield 2020 0,31%
Capitalization 2 968 M 315 M 315 M
EV / Sales 2019
EV / Sales 2020 4,13x
Nbr of Employees -
Free-Float 45,5%
Chart PROBI AB (PUBL)
Duration : Period :
Probi AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROBI AB (PUBL)
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 2
Average target price
Last Close Price 260,50 
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers
NameTitle
Tom Juhani Rönnlund Chief Executive Officer
Jean-Yves Parisot Chairman
Andy McShea Vice President-Operations
Henrik Lundkvist Chief Financial Officer
Niklas Brandt Vice President-Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
PROBI AB (PUBL)17.34%315
BY-HEALTH CO., LTD.14.92%4 151
BALCHEM CORPORATION-0.96%3 253
THE SIMPLY GOOD FOODS COMPANY-40.33%1 624
MEDIFAST, INC.-10.48%1 206
KOLMARBNH CO LTD--.--%965